Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122685 | 0.86 | HRH3 (0.50) | HRH3KCNH2CYP2D6HTR4 | |
| SCHEMBL10447140 | 0.83 | HRH3 (0.45) | HRH3KCNH2CYP2D6HTR4NCF1 | |
| SCHEMBL4374285 | 0.83 | HRH3 (0.45) | HRH3KCNH2CYP2D6HTR4ALDH1A1 | |
| SCHEMBL4377486 | 0.83 | HRH3 (0.45) | HRH3KCNH2CYP2D6HTR4ALDH1A1 | |
| SCHEMBL31273027 | 0.82 | HRH3 (0.47) | HRH3KCNH2CYP2D6HTR4ALDH1A1 | |
| SCHEMBL31272933 | 0.82 | HRH3 (0.47) | HRH3KCNH2CYP2D6HTR4ALDH1A1 | |
| SCHEMBL16376649 | 0.82 | HRH3 (0.42) | HRH3KCNH2CYP2D6 | |
| SCHEMBL178288 | 0.80 | HRH3 (0.46) | HRH3KCNH2CYP2D6HTR4 | |
| SCHEMBL4385963 | 0.79 | HRH3 (0.46) | HRH3KCNH2CYP2D6HTR4ALDH1A1 | |
| SCHEMBL102140 | 0.78 | HRH3 (0.45) | HRH3KCNH2CYP2D6HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | ASANA BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188654-B2 | Uses of pyrimido-pyridazinones to treat cancer | MKI67, DPYD, TYMP | HRH3 2015/4885KCNH2 2545/4885CYP2D6 419/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | HRH3 2015/4885KCNH2 2545/4885CYP2D6 419/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | HRH3 866/4885KCNH2 2093/4885CYP2D6 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.